Patents Assigned to Ansun Biopharma, Inc.
  • Patent number: 11697803
    Abstract: The present disclosure provides methods for releasing intracellular proteins. The method allows isolation of the protein of interest from the cell without the requirement for mechanical disruption of the cells, without the need for isolation of the cells from the culture media, and without the need for removal of the cells from the culture media.
    Type: Grant
    Filed: July 15, 2019
    Date of Patent: July 11, 2023
    Assignee: Ansun Biopharma, Inc.
    Inventor: Stephen Hawley
  • Patent number: 11241486
    Abstract: Methods and compositions for treating Middle East respiratory syndrome coronavirus (MERS-CoV) infection using polypeptides having sialidase activity are provided herein.
    Type: Grant
    Filed: January 27, 2020
    Date of Patent: February 8, 2022
    Assignee: Ansun Biopharma, Inc.
    Inventor: Ronald D. Moss
  • Publication number: 20200297822
    Abstract: The present invention provides a method of reducing the quantity of mucus in the respiratory tract of a subject with elevated levels of mucus in said respiratory tract. The method includes administering to the subject a compound or composition containing a therapeutically effective amount of a fusion protein comprising a sialidase or an active portion thereof and an anchoring domain. The therapeutically effective amount comprises an amount of the fusion protein that results in a reduction of the quantity of mucus in the respiratory tract after administration of the compound or composition when compared to the quantity of mucus present prior to administration of the compound or composition.
    Type: Application
    Filed: June 4, 2020
    Publication date: September 24, 2020
    Applicant: Ansun Biopharma, Inc.
    Inventors: Fang Fang, David Wurtman, Ron Moss, Michael P. Malakhov
  • Patent number: 10583086
    Abstract: Microspheres are produced by contacting an aqueous solution of a protein or other macromolecule with an organic solvent and a counterion, and chilling the solution. The microspheres are useful for preparing pharmaceuticals of defined dimensions.
    Type: Grant
    Filed: September 25, 2017
    Date of Patent: March 10, 2020
    Assignee: Ansun Biopharma, Inc.
    Inventors: Michael P. Malakhov, Fang Fang
  • Patent number: 10525109
    Abstract: The present invention provides new compositions and methods for preventing and treating pathogen infection. In particular, the present invention provides compounds having an anchoring domain that anchors the compound to the surface of a target cell, and a therapeutic domain that can act extracellularly to prevent infection of a target cell by a pathogen, such as a virus. The present invention also comprises therapeutic compositions having sialidase activity, including protein-based compounds having sialidase catalytic domains. Compounds of the invention can be used for treating or preventing pathogen infection, and for treating and reducing allergic and inflammatory responses. The invention also provides compositions and methods for enhancing transduction of target cells by recombinant viruses. Such compositions and methods can be used in gene therapy.
    Type: Grant
    Filed: August 22, 2017
    Date of Patent: January 7, 2020
    Assignee: Ansun Biopharma, Inc.
    Inventors: Fang Fang, Michael P. Malakhov
  • Patent number: 10351828
    Abstract: The present disclosure provides methods for releasing intracellular proteins. The method allows isolation of the protein of interest from the cell without the requirement for mechanical disruption of the cells, without the need for isolation of the cells from the culture media, and without the need for removal of the cells from the culture media.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: July 16, 2019
    Assignee: Ansun Biopharma, Inc.
    Inventor: Stephen Hawley
  • Patent number: 10328128
    Abstract: The present disclosure provides compositions and methods for treating an infection by EV-D68. In particular, the present disclosure provides methods that entail administering agents having an anchoring domain that anchors the compound to the surface of a target cell, and a sialidase domain that can act extracellularly to inhibit infection of a target cell by EV-D68.
    Type: Grant
    Filed: September 17, 2015
    Date of Patent: June 25, 2019
    Assignee: Ansun Biopharma, Inc.
    Inventor: Ronald B. Moss
  • Patent number: 10300116
    Abstract: The present disclosure provides novel compositions and methods for treating infection by a viral pathogen, e.g., a BK or JC polyomavirus, using agents having sialidase activity. In particular, the present disclosure provides methods that entail administering agents having an anchoring domain that anchors the compound to the surface of a target cell, and a sialidase domain that can act extracellularly to inhibit infection of a target cell by a pathogen.
    Type: Grant
    Filed: June 10, 2014
    Date of Patent: May 28, 2019
    Assignee: Ansun Biopharma, Inc.
    Inventor: Ronald D. Moss
  • Publication number: 20180140683
    Abstract: The present invention provides a method of reducing the quantity of mucus in the respiratory tract of a subject with elevated levels of mucus in said respiratory tract. The method includes administering to the subject a compound or composition containing a therapeutically effective amount of a fusion protein comprising a sialidase or an active portion thereof and an anchoring domain. The therapeutically effective amount comprises an amount of the fusion protein that results in a reduction of the quantity of mucus in the respiratory tract after administration of the compound or composition when compared to the quantity of mucus present prior to administration of the compound or composition.
    Type: Application
    Filed: January 8, 2018
    Publication date: May 24, 2018
    Applicant: Ansun Biopharma, Inc.
    Inventors: Fang Fang, David Wurtman, Ron Moss, Michael P. Malakhov
  • Patent number: 9764007
    Abstract: The present invention provides new compositions and methods for preventing and treating pathogen infection. In particular, the present invention provides compounds having an anchoring domain that anchors the compound to the surface of a target cell, and a therapeutic domain that can act extracellularly to prevent infection of a target cell by a pathogen, such as a virus. The present invention also comprises therapeutic compositions having sialidase activity, including protein-based compounds having sialidase catalytic domains. Compounds of the invention can be used for treating or preventing pathogen infection, and for treating and reducing allergic and inflammatory responses. The invention also provides compositions and methods for enhancing transduction of target cells by recombinant viruses. Such compositions and methods can be used in gene therapy.
    Type: Grant
    Filed: November 30, 2015
    Date of Patent: September 19, 2017
    Assignee: Ansun Biopharma, Inc.
    Inventors: Fang Fang, Michael P. Malakhov
  • Patent number: 9700602
    Abstract: Microparticle formulations of a sialidase fusion protein are produced by contacting an aqueous solution of a protein or other active agent with an organic solvent, a counterion and a scavenging agent, and chilling the solution. The microparticles are useful for preparing stable, uniform pharmaceuticals of predetermined defined dimensions.
    Type: Grant
    Filed: May 16, 2016
    Date of Patent: July 11, 2017
    Assignee: Ansun Biopharma, Inc.
    Inventors: Michael P. Malakhov, Tiejun Li
  • Publication number: 20160120961
    Abstract: The present disclosure provides novel compositions and methods for treating an infection of the skin resulting from an infection of a member of the Orthopolyomavirus virus family. In particular, the present disclosure provides compounds having an anchoring domain that anchors the compound to the surface of a target cell, and a sialidase domain that can act extracellularly to inhibit infection of a target cell by a pathogen, such as a virus. The present disclosure also comprises therapeutic compositions having sialidase activity, including protein based compounds having sialidase catalytic domains. Compounds of the disclosure can be used for treating pathogenic infection to the skin.
    Type: Application
    Filed: June 10, 2014
    Publication date: May 5, 2016
    Applicant: ANSUN BIOPHARMA, INC.
    Inventor: Ronald D. Moss
  • Patent number: 9212353
    Abstract: The present invention provides new compositions and methods for preventing and treating pathogen infection. In particular, the present invention provides compounds having an anchoring domain that anchors the compound to the surface of a target cell, and a therapeutic domain that can act extracellularly to prevent infection of a target cell by a pathogen, such as a virus. The present invention also comprises therapeutic compositions having sialidase activity, including protein-based compounds having sialidase catalytic domains. Compounds of the invention can be used for treating or preventing pathogen infection, and for treating and reducing allergic and inflammatory responses. The invention also provides compositions and methods for enhancing transduction of target cells by recombinant viruses. Such compositions and methods can be used in gene therapy.
    Type: Grant
    Filed: May 12, 2014
    Date of Patent: December 15, 2015
    Assignee: Ansun Biopharma, Inc.
    Inventors: Fang Fang, Michael Malakhov
  • Publication number: 20140342006
    Abstract: A method for preparing a microparticle suspension, which comprises: (a) providing protein microparticles having a median diameter between 5 and 13 microns and a GSD less than 2.5; (b) combining the microparticles with a liquid, pharmaceutically acceptable, water miscible media to create a first mixture; (c) adding an aqueous media to the first mixture to create second mixture; and (d) mixing the second mixture to create a microparticle suspension is described. The suspension are injectable even when they contain a relatively high concentration of protein.
    Type: Application
    Filed: March 13, 2014
    Publication date: November 20, 2014
    Applicant: Ansun Biopharma, Inc.
    Inventor: Tiejun Li
  • Publication number: 20140328820
    Abstract: The present invention provides new compositions and methods for preventing and treating pathogen infection. In particular, the present invention provides compounds having an anchoring domain that anchors the compound to the surface of a target cell, and a therapeutic domain that can act extracellularly to prevent infection of a target cell by a pathogen, such as a virus. The present invention also comprises therapeutic compositions having sialidase activity, including protein-based compounds having sialidase catalytic domains. Compounds of the invention can be used for treating or preventing pathogen infection, and for treating and reducing allergic and inflammatory responses. The invention also provides compositions and methods for enhancing transduction of target cells by recombinant viruses. Such compositions and methods can be used in gene therapy.
    Type: Application
    Filed: May 12, 2014
    Publication date: November 6, 2014
    Applicant: Ansun Biopharma, Inc.
    Inventors: Fang Fang, Michael Malakhov
  • Publication number: 20140308729
    Abstract: The present disclosure provides methods for releasing intracellular proteins. The method allows isolation of the protein of interest from the cell without the requirement for mechanical disruption of the cells, without the need for isolation of the cells from the culture media, and without the need for removal of the cells from the culture media.
    Type: Application
    Filed: March 14, 2014
    Publication date: October 16, 2014
    Applicant: Ansun Biopharma, Inc.
    Inventor: Stephen Hawley
  • Publication number: 20140134150
    Abstract: Microspheres are produced by contacting an aqueous solution of a protein or other macromolecule with an organic solvent and a counterion, and chilling the solution. The microspheres are useful for preparing pharmaceuticals of defined dimensions.
    Type: Application
    Filed: January 6, 2014
    Publication date: May 15, 2014
    Applicant: Ansun Biopharma, Inc.
    Inventors: Michael P. Malakhov, Fang Fang
  • Patent number: 8722869
    Abstract: The present invention provides new compositions and methods for preventing and treating pathogen infection. In particular, the present invention provides compounds having an anchoring domain that anchors the compound to the surface of a target cell, and a therapeutic domain that can act extracellularly to prevent infection of a target cell by a pathogen, such as a virus. The present invention also comprises therapeutic compositions having sialidase activity, including protein-based compounds having sialidase catalytic domains. Compounds of the invention can be used for treating or preventing pathogen infection, and for treating and reducing allergic and inflammatory responses. The invention also provides compositions and methods for enhancing transduction of target cells by recombinant viruses. Such compositions and methods can be used in gene therapy.
    Type: Grant
    Filed: August 19, 2013
    Date of Patent: May 13, 2014
    Assignee: Ansun Biopharma, Inc.
    Inventors: Fang Fang, Michael P. Malakhov
  • Publication number: 20140099696
    Abstract: Microspheres are produced by contacting a solution of a macromolecule or small molecule in a solvent with an antisolvent and a counterion, and chilling the solution. The microspheres are useful for preparing pharmaceuticals, nutraceuticals, cosmetic products and the like of defined dimensions.
    Type: Application
    Filed: April 30, 2013
    Publication date: April 10, 2014
    Applicant: Ansun Biopharma, Inc.
    Inventors: Michael P. Malakhov, Fang Fang
  • Patent number: 8623419
    Abstract: Microspheres are produced by contacting an aqueous solution of a protein or other macromolecule with an organic solvent and a counterion, and chilling the solution. The microspheres are useful for preparing pharmaceuticals of defined dimensions.
    Type: Grant
    Filed: November 4, 2011
    Date of Patent: January 7, 2014
    Assignee: Ansun Biopharma, Inc.
    Inventors: Michael P. Malakhov, Fang Fang